National Institute of Cancer Research, National Health Research Institutes, Zhunan, Miaoli, Taiwan.
Institute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu, Taiwan.
Sci Rep. 2017 Dec 5;7(1):17024. doi: 10.1038/s41598-017-17126-2.
Cdc7-Dbf4 kinase plays a key role in the initiation of DNA replication and contributes to the replication stress in cancer. The activity of human Cdc7-Dbf4 kinase remains active and acts as an effector of checkpoint under replication stress. However, the downstream targets of Cdc7-Dbf4 contributed to checkpoint regulation and replication stress-support function in cancer are not fully identified. In this work, we showed that aberrant Cdc7-Dbf4 induces DNA lesions that activate ATM/ATR-mediated checkpoint and homologous recombination (HR) DNA repair. Using a phosphoproteome approach, we identified HSP90-S164 as a target of Cdc7-Dbf4 in vitro and in vivo. The phosphorylation of HSP90-S164 by Cdc7-Dbf4 is required for the stability of HSP90-HCLK2-MRN complex and the function of ATM/ATR signaling cascade and HR DNA repair. In clinically, the phosphorylation of HSP90-S164 indeed is increased in oral cancer patients. Our results indicate that aberrant Cdc7-Dbf4 enhances replication stress tolerance by rewiring ATR/ATM mediated HR repair through HSP90-S164 phosphorylation and by promoting recovery from replication stress. We provide a new solution to a subtyping of cancer patients with dominant ATR/HSP90 expression by combining inhibitors of ATR-Chk1, HSP90, or Cdc7 in cancer combination therapy.
Cdc7-Dbf4 激酶在 DNA 复制的起始中起着关键作用,并有助于癌症中的复制应激。人类 Cdc7-Dbf4 激酶的活性保持活跃,并在复制应激下作为检查点的效应物发挥作用。然而,Cdc7-Dbf4 的下游靶标在癌症中的检查点调控和复制应激支持功能尚未完全确定。在这项工作中,我们表明,异常的 Cdc7-Dbf4 诱导激活 ATM/ATR 介导的检查点和同源重组 (HR) DNA 修复的 DNA 损伤。通过磷酸化蛋白质组学方法,我们鉴定了 HSP90-S164 是体外和体内 Cdc7-Dbf4 的靶标。Cdc7-Dbf4 对 HSP90-S164 的磷酸化对于 HSP90-HCLK2-MRN 复合物的稳定性和 ATM/ATR 信号级联和 HR DNA 修复的功能是必需的。在临床上,口腔癌患者中 HSP90-S164 的磷酸化确实增加了。我们的结果表明,异常的 Cdc7-Dbf4 通过 HSP90-S164 磷酸化重排 ATR/ATM 介导的 HR 修复,以及通过促进从复制应激中恢复,增强了对复制应激的耐受性。我们通过在癌症联合治疗中结合 ATR-Chk1、HSP90 或 Cdc7 的抑制剂,为具有显性 ATR/HSP90 表达的癌症患者提供了一种新的亚型解决方案。